NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer

Maija Wolf (Corresponding Author), Henrik Edgren, Aslaug Muggerud, Sami Kilpinen, Pia Huusko, Therese Sørlie, Spyro Mousses, Olli Kallioniemi

Research output: Contribution to journalArticleScientificpeer-review

16 Citations (Scopus)


Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.
Original languageEnglish
Pages (from-to)169-173
JournalCellular Oncology
Issue number3
Publication statusPublished - 2005
MoE publication typeA1 Journal article-refereed


  • NMD
  • microarray
  • mutation
  • tumor suppressor gene


Dive into the research topics of 'NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer'. Together they form a unique fingerprint.

Cite this